Researchers identify two risk factors that indicate higher risk of aggressive prostate cancer

Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and meaningful survival in cisplatin-ineligible patients with locally advanced or metastatic

Medical device company Becton Dickinson (BD) may be nearing the end of a shortage of plastic bottles used to contain blood culture media, a company